olmesartan has been researched along with trimethoprim in 5 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (trimethoprim) | Trials (trimethoprim) | Recent Studies (post-2010) (trimethoprim) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 6,989 | 845 | 894 |
| Protein | Taxonomy | olmesartan (IC50) | trimethoprim (IC50) |
|---|---|---|---|
| Chain A, Dihydrofolate reductase | Bacillus anthracis | 77200 | |
| Chain A, dihydrofolate reductase (DHFR) | Bacillus anthracis | 77200 | |
| Dihydrofolate reductase | Mycobacterium avium | 0.2588 | |
| Dihydrofolate reductase | Homo sapiens (human) | 1.8206 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.3493 | |
| Dihydrofolate reductase type 1 | Escherichia coli | 0.25 | |
| Dihydrofolate reductase | Neisseria gonorrhoeae | 0.45 | |
| Thymidylate synthase | Homo sapiens (human) | 3.405 | |
| Dihydrofolate reductase | Staphylococcus aureus | 0.0875 | |
| Thymidylate synthase | Escherichia coli K-12 | 3.405 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.6064 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.01 | |
| Dihydrofolate reductase type 1 from Tn4003 | Staphylococcus aureus | 0.023 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.7 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.7061 | |
| Dihydrofolate reductase | Candida albicans | 0.1361 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 2.7 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.45 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 2.73 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 2.8 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 3.2206 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium berghei ANKA | 0.12 | |
| Dihydrofolate reductase | Streptococcus pneumoniae TIGR4 | 0.0297 | |
| Dihydrofolate reductase | Lactococcus lactis subsp. lactis Il1403 | 0.45 | |
| Dihydrofolate reductase | Bacillus anthracis | 4.77 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 1.244 | |
| Dihydrofolate reductase | Pneumocystis jirovecii | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
5 other study(ies) available for olmesartan and trimethoprim
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |